AC
ADAP

Ascend Capital’s Adaptimmune Therapeutics ADAP Stock Holding History

Ascend Capital’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-50,000
Closed -$353K – 136
2016
Q3 		$353K Sell
50,000
-164,794
-77% -$1.26M 0.02% 114
2016
Q2 		$1.75M Buy
214,794
+164,794
+330% +$1.55M 0.11% 122
2016
Q1 		$406K Buy
+50,000
New +$409K 0.04% 92

Other funds holding ADAP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Ascend Capital's ADAP Position: Q4 2016 in Review

Ascend Capital sold out of Adaptimmune Therapeutics (ADAP) in Q4 2016, closing a stake of 50,000 shares — an estimated $353K sold.

Ascend Capital first reported a position in ADAP in Q1 2016 and held it in 3 quarters. The position peaked at $1.75M in Q2 2016. 40 funds tracked by Wall St. Rank hold ADAP as of Q4 2016.

  • Ascend Capital reported no remaining Adaptimmune Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Ascend Capital sold 50,000 Adaptimmune Therapeutics shares in Q4 2016, an estimated $353K.
  • Ascend Capital first reported a position in Adaptimmune Therapeutics in Q1 2016 and held it in 3 quarters.
  • Ascend Capital's Adaptimmune Therapeutics position peaked at $1.75M in Q2 2016.
  • 40 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2016.

Based on Ascend Capital's 13F filing for Q4 2016, filed 13 Feb 2017.